# Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

> **NCT07321652** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 466 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Sonrotoclax
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT07321652
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2038-09-30
- **Target enrollment:** 466 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321652, "Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07321652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*